Merlin Crossley to take Dean's chair at the University of New South Wales in January 2010. [ + ]

IVD Australia is a recently formed association that represents companies that manufacture and supply in-vitro diagnostics in Australia.

Traditional notions of biological classification based on morphology are being shaken up by the new practice of molecular taxonomy. But far from being contradictory approaches, they may end up being complementary. [ + ]

What does the mutiny on the Bounty have to do with the genetics of migraine? Lyn Griffiths talks about her voyage to Norfolk Island, the last home of the Bounty mutineers, to find out what they can teach us about migraine. [ + ]

Two hundred outstanding national and international mid-career researchers have been awarded ARC Future Fellowships in an attempt to address the gap in opportunities for mid-career researchers in Australia.

New drug application for targeted anti-leukaemia drug completed, mid-2010 launch expected. [ + ]

Help is at hand for medical researchers looking for philanthropic support to deliver health benefits to the community.

X and Y chromosomes have been shown to exchange DNA, refuting the scientific theory that the two chromosomes do not communicate at all.

$15 million capital raising enough to fund trials for over two years. [ + ]

Contamination and how scientists can help to clean up will be a focus at CleanUp 09, an international summit being hosted by CRC CARE.

At the intersection of biology and chemistry is where Mark von Itzstein focuses his attention, constantly looking for ways to stay one step in front of diseases like influenza. [ + ]

Professor John Prins has been appointed as CEO and Institute Director at the Mater Medical Research Institute.

A technique for stabilising enzymes could lead to better biosensors, disease therapeutics and diagnostic reagents and non-laboratory applications, including environmental remediation.

The University of Western Australia is considering its options following a judgement from the Full Bench of the Federal Court relating to the University’s right to protect its investment in intellectual property developed by its staff.

Pfizer will pay a total of US$2.3 billion to settle fraud claims resulting from its past promotional practices.